SRRM1 (serine and arginine repetitive matrix 1) is a multifunctional splicing factor that serves as a core component of pre- and post-splicing mRNP complexes. Functionally, SRRM1 promotes both constitutive and exonic splicing enhancer (ESE)-dependent splicing activation by bridging sequence-specific SR family proteins with basal snRNP factors of the spliceosome 1. The protein binds pre-mRNA and spliced mRNA 20-25 nucleotides upstream of exon-exon junctions and stimulates mRNA 3'-end cleavage independently of exon junction complex formation. In cancer pathology, SRRM1 dysregulation represents a hallmark of aggressive malignancies. In prostate cancer, elevated plasma SRRM1 levels discriminate patients from controls and correlate with castration-resistant progression and AR-V7 expression 2. In hepatocellular carcinoma, SRRM1 overexpression promotes proliferation, migration, and invasion through JAK/STAT pathway activation 3. SRRM1 also facilitates oncogenic splicing variant generation including AR-v7 and PKM2 4. Beyond cancer, heterozygous SRRM1 loss-of-function variants cause neurodevelopmental disorders characterized by developmental delay, intellectual disability, and impaired neurite outgrowth 5. Additionally, SRRM1 serves as a potential biomarker in viral infection contexts, responding to viral activity in autoimmune diseases 6. These findings establish SRRM1 as both a fundamental splicing regulator and an emerging therapeutic target across multiple disease contexts.